UPS: Investing US$48m for Cold Prescription Deliveries

Temperature control failures in pharmaceutical distribution carry an estimated annual cost of up to US$35bn.

For healthcare organisations moving critical treatments from manufacturers to patients, this makes reliable cold chain infrastructure a necessity rather than an option.

UPS has committed US$48m to expand its temperature-controlled freight cross-dock facilities across 27 locations in Europe, Asia and the Americas.

The investment targets the company's ability to manage products requiring strict thermal parameters between manufacturers and healthcare providers.

Pharmaceutical transport requirements

Medicines typically require maintenance within two to eight degrees Celsius, frozen conditions or 15 C to 25 C throughout transit. Deviations from these ranges could compromise drug efficacy and patient safety.

According to the World Health Organisation, temperature failures contribute towards up to 50% of global vaccine waste. This places considerable pressure on logistics providers to maintain controlled environments across air and ground movements.

UPS operates more than 19.2 million square feet of cGMP and GDP-compliant healthcare distribution space globally. The network handles inventory management, cold chain packaging and shipping, storage and fulfilment of medical devices, as well as lab and clinical trial logistics across more than 200 countries and territories.

The new cross-dock facilities will optimise speed and short-term storage within controlled temperature requirements. This could strengthen the company's capacity to meet varying pharmaceutical specifications with reduced handoff risks during critical transport phases.

Biologics and patient access

According to Growth Market Reports, industry demand for temperature-sensitive biologics is anticipated to grow to US$39.1bn through 2033. Cell and gene treatments, mRNA platforms and GLP-1 injectables are entering the market with thermal management needs more complex than traditional pharmaceuticals.

PharmaSource states that approximately one in three newly approved drugs is a biologic. Created from living cells, more than 85% of them require temperature-controlled handling as a result.

"We have aligned our investments with our Healthcare customers' specialised needs," says Kate Gutmann, EVP and President of International, Healthcare and Supply Chain Solutions at UPS.

"Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world.

"This effort – and all of our work in healthcare logistics – extends from a deep understanding that we're doing more than moving packages.

"We are helping patients access the medications and treatments they need."

Integrated network approach

Fragmented networks or increased handoffs raise the risk of thermal excursions during pharmaceutical transport.

A single integrated network could reduce these risks through consolidated accountability and oversight.

UPS uses a 24/7/365 control tower that monitors shipments, identifies risks and supports intervention to maintain product movement.

Customers receive real-time oversight for each shipment through this system.

"Biologics and personalised treatments are driving better, more targeted care for patients," adds John Bolla, President of UPS Healthcare.

"These investments reflect our commitment to strengthening our end-to-end supply chain that helps protect innovative treatments and diagnostics, supporting better patient outcomes."

European and Asian expansion

The investment builds on recent acquisitions including Bomi Group, Frigo Trans and BPL throughout Europe, as well as Andlauer Healthcare Group in North America.

UPS has also expanded its Incheon, Korea air hub to manage pharmaceutical trade flows.

These additions to the network target the infrastructure needed to support gene therapies and biologics requiring uninterrupted cold chain custody.

As scientific breakthroughs create new therapeutic options, supply chain requirements for these products continue to evolve.

The 27 facilities receiving investment are located in key pharmaceutical manufacturing and distribution markets.

This strategic positioning could allow faster response times when managing time-sensitive treatments requiring controlled environments throughout transport.